Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

IntroductionThe complement system is a key component of the innate immune system, and its aberrant activation underlies the pathophysiology of various diseases. Zilucoplan is a macrocyclic peptide that binds and inhibits the cleavage/activation of human complement component 5 (C5). We present in vit...

Full description

Bibliographic Details
Main Authors: Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, Michelle D. Hoarty, Rohit Vyasamneni, Douangsone D. Vadysirisack, Zhong Ma, Nanqun Zhu, Jian-Guo Wang, Charlie Bu, Bestine Cong, Elizabeth Palmer, Petra W. Duda, Camil Sayegh, Alonso Ricardo
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Immunology
Subjects:
complement activation
C5 cleavage
C5 R885 variants
C5b6
MAC formation
macrocyclic peptide inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213920/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213920/full

Similar Items